转录因子AP-2γ在恶性肿瘤中的研究进展

doi:10.16352/j.issn.1001-6325.2022.12.1955

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (12): 1955-1959.doi: 10.16352/j.issn.1001-6325.2022.12.1955

转录因子AP-2γ在恶性肿瘤中的研究进展

陈康, 程帆^*

武汉大学人民医院泌尿外科, 湖北武汉 430060

收稿日期:2021-07-15 修回日期:2021-12-17 出版日期:2022-12-05 发布日期:2022-11-23
通讯作者: ^* urology1969@aliyun.com
基金资助:
基于健康大数据的智能医疗服务算法与应用(2019AEA170)

Research progress of transcription factor AP-2 γ in malignant tumors

CHEN Kang, CHENG Fan^*

Department of Urology, Renmin Hospital of Wuhan University, Wuhan 430060, China

Received:2021-07-15 Revised:2021-12-17 Online:2022-12-05 Published:2022-11-23
Contact: ^* urology1969@aliyun.com

摘要/Abstract

摘要： 转录因子激活蛋白2γ(AP-2γ)不仅在早期胚胎发育中调节着控制滋养外胚层细胞增殖和分化的遗传程序,还参与调控乳腺癌、肺癌、睾丸癌、黑色素瘤及胰腺癌等多种肿瘤发展过程中的关键靶标,从而影响肿瘤的发生发展。因此,关注AP-2γ在肿瘤发生发展过程中的调控机制,可为肿瘤的诊断与治疗提供新的思路。

关键词: 转录因子, AP-2γ, 胚胎发育, 肿瘤

Abstract: Transcription factor AP-2γ regulates not only the genetic procedures that control the proliferation and differentiation of trophoblast cells during early embryonic development, but also is the key target in the development of breast cancer, lung cancer, testicular cancer, melanoma and pancreatic cancer, thus affecting the occurrence and development of tumors. Therefore, paying attention to the regulatory mechanisms of AP-2γ in the occurrence and development of malignant tumors may provide new ideas for the diagnosis and treatment of tumors.

Key words: transcription factor, AP-2γ, embryonic development, tumor

中图分类号:

R730.53

陈康, 程帆. 转录因子AP-2γ在恶性肿瘤中的研究进展[J]. 基础医学与临床, 2022, 42(12): 1955-1959.

CHEN Kang, CHENG Fan. Research progress of transcription factor AP-2 γ in malignant tumors[J]. Basic & Clinical Medicine, 2022, 42(12): 1955-1959.

参考文献

[1]齐力,候艳,宋丽华. 转录因子YY1促进下咽癌细胞的迁移能力[J]. 基础医学与临床,2019,39:1320-1324.
[2]Dooley CM, Wali N, Sealy IM, et al. The gene regulatory basis of genetic compensation during neural crest induction[J]. PLoS Genet, 2019, 15:e1008213.doi: 10.1371/journal.pgen.1008213.
[3]Kołat D, Kałuzińskaz, Bednarek AK, et al. WWOX loses the ability to regulate oncogenic Ap-2γ and synergizes with tumor suppressor AP-2α in high-grade bladder cancer[J]. Cancers, 2021, 13:2957.doi: 10.3390/cancers13122957.
[4]Kołat D, Kałuzińskaz, Bednarek AK, et al. The biol-ogical characteristics of transcription factors AP-2α and AP-2γ and their importance in various types of cancers[J]. Biosci Rep, 2019, 39:BSR20181928.doi: 10.1042/BSR20181928.
[5]Li L, Wang Y, Torkelson JL, et al. TFAP2C- and p63-dependent networks sequentially rearrange chromatin landscapes to drive human epidermal lineage commitment[J]. Cell Stem Cell, 2019, 24:271-284.doi: 10.1016/j.stem.2018.12.012.
[6]Wang Y, Chen S, Jiang Q, et al. TFAP2C facilitates somatic cell reprogramming by inhibiting c-Myc-dependent apoptosis and promoting mesenchymal-to-epithelial transition[J]. Cell Death Dis, 2020, 11:482.doi: 10.1038/s41419-020-2684-9.
[7]Kołat D, Kałuzińskaz, Płuciennik E. Fragile gene WWOX guides TFAP2A/TFAP2C-dependent actions against tumor progression in grade ii bladder cancer[J]. Front Oncol, 2021, 11:621060.doi: 10.3389/fonc.2021.621060.
[8]Li H, Goswami PC, Domann FE. AP-2gamma induces p21 expression, arrests cell cycle, and inhibits the tumor growth of human carcinoma cells[J]. Neoplasia, 2006, 8:568-577.
[9]Franke CM, Gu VW, Grimm BG, et al. TFAP2C regu-lates carbonic anhydrase XII in human breast cancer[J]. Oncogene, 2020, 39:1290-1301.
[10]Wu VT, Kiriazov B, Koch KE, et al. A TFAP2C gene signature is predictive of outcome in HER2-positive breast cancer[J]. Mol Cancer Res, 2020, 18:46-56.
[11]Park JM, Wu T, Cyr AR, et al. The role of Tcfap2c in tumorigenesis and cancer growth in an activated Neu model of mammary carcinogenesis[J]. Oncogene, 2015, 34:6105-6114.
[12]Li K, Xu C, Du Y, et al. Comprehensive epigenetic analyses reveal master regulators driving lung metastasis of breast cancer[J]. J Cell Mol Med, 2019, 23:5415-5431.
[13]Vernieri C, Milano M, Brambilla M, et al. Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: current knowledge, new research direc-tions and therapeutic perspectives[J]. Crit Rev Oncol Hematol, 2019, 139:53-66.
[14]Cheng C, Ai Z, Zhao L. Comprehensive analysis of the expression and prognosis for TFAP2 in human lung carcinoma[J]. Genes Genom, 2020, 42:779-789.
[15]Do H, Kim D, Kang J, et al. TFAP2C increases cell proliferation by downregulating GADD45B and PMAIP1 in non-small cell lung cancer cells[J]. Biol Res, 2019, 52:35.doi: 10.1186/s40659-019-0244-5.
[16]Kim W, Kim E, Lee S, et al. TFAP2C-mediated upregulation of TGFBR1 promotes lung tumorigenesis and epithelial-mesenchymal transition[J]. Exp Mol Med, 2016, 48:e273.doi: 10.1038/emm.2016.125.
[17]Lal G, Contreras PG, Kulak M, et al. Human melanoma cells over-express extracellular matrix 1 (ECM1) which is regulated by TFAP2C[J]. PLoS One, 2013, 8:e73953.doi: 10.1371/journal.pone.0073953.
[18]Penna E, Orso F, Cimino D, et al. MicroRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C[J]. Embo j, 2011, 30:1990-2007.
[19]Chang WF, Peng M, Hsu J, et al. Effects of survival motor neuron protein on germ cell development in mouse and human[J]. Int J Mol Sci, 2021, 22:661.doi: 10.3390/ijms22020661.
[20]Senft AD, Bikoff EK, Robertson EJ, et al. Genetic dissection of Nodal and Bmp signalling requirements during primordial germ cell development in mouse[J]. Nat Commun, 2019, 10:1089.doi: 10.1038/s41467-019-09052-w.
[21]Xiong G, Huang H, Feng M, et al. miR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma[J]. J Exp Clin Cancer Res, 2018, 37:76.doi: 10.1186/s13046-018-0739-x.
[22]Li L, Zheng YL, Jiang C, et al. HN1L-mediated transcriptional axis AP-2γ/METTL13/TCF3-ZEB1 drives tumor growth and metastasis in hepatocellular carcinoma[J]. Cell Death Differ, 2019, 26:2268-2283.
[23]Lin CY, Lee LY, Wang TH, et al. Palbociclib promotes dephosphorylation of NPM/B23 at threonine 199 and inhibits endometrial cancer cell growth[J]. Cancers, 2019, 11:1025.doi: 10.3390/cancers11071025.
[24]Bardelli V, Arniani S, Pierini V, et al. T-cell acute lymphoblastic leukemia: biomarkers and their clinical usefulness[J]. Genes, 2021, 12:1118.doi: 10.3390/genes12081118.
[25]Zhuang M, Chaolumen Q, Li L, et al. miR-29b-3p cooperates with miR-29c-3p to affect the malignant biological behaviors in T-cell acute lymphoblastic leukemia via TFAP2C/GPX1 axis[J]. Biochem Biophys Res Commun, 2020, 527:511-517.

转录因子AP-2γ在恶性肿瘤中的研究进展

Research progress of transcription factor AP-2 γ in malignant tumors

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	夏雨佳, 杨振丽, 刘玉琴. 肿瘤类器官临床前转化研究及应用[J]. 基础医学与临床, 2024, 44(9): 1214-1218.
[2]	刘保清, 黄容, 卢艳, 李凯, 张宁, 刘长征, 宋伟. 胃癌类器官在基础研究与临床应用中的进展[J]. 基础医学与临床, 2024, 44(9): 1219-1222.
[3]	李阳, 朱蕾. 真核延伸因子2激酶是治疗肿瘤的潜在新靶标[J]. 基础医学与临床, 2024, 44(7): 1039-1043.
[4]	陈笑天, 陈翀, 罗云萍. MAFB对肿瘤相关巨噬细胞极化及功能的影响[J]. 基础医学与临床, 2024, 44(7): 965-973.
[5]	谭树芬, 何利平, 杨琳琳, 杨谢兰, 杨宏英, 姚明姣, 李树清. TBL与工作坊整合教学法在妇科肿瘤学临床教学中的应用[J]. 基础医学与临床, 2024, 44(7): 1054-1057.
[6]	周玥, 童安莉. 嗜铬细胞瘤/副神经节瘤免疫微环境[J]. 基础医学与临床, 2024, 44(6): 742-747.
[7]	张沥元, 杜函泽, 潘慧. 治疗下丘脑性肥胖的药物研究进展[J]. 基础医学与临床, 2024, 44(5): 729-732.
[8]	王婷婷, 郭丹, 陆君阳, 徐徕, 董海涛, 林佃新, 肖毅. 结直肠神经内分泌肿瘤细胞突变类型分析[J]. 基础医学与临床, 2024, 44(4): 523-527.
[9]	王子豪, 夏小超, 李舜. 跨膜蛋白质在恶性肿瘤中作用的研究进展[J]. 基础医学与临床, 2024, 44(3): 398-402.
[10]	吴玉红, 喻才元, 叶石才. NMES1基因在恶性肿瘤中作用的研究进展[J]. 基础医学与临床, 2024, 44(3): 403-407.
[11]	南璐, 郭梦杰, 高雅楠, 贾红燕. 膜联蛋白A家族成员在乳腺癌中作用机制的研究进展[J]. 基础医学与临床, 2024, 44(3): 393-397.
[12]	陈雪, 罗添, 魏超君. 溶血磷脂酰胆碱酰基转移酶1在肿瘤中作用的研究进展[J]. 基础医学与临床, 2024, 44(2): 256-259.
[13]	刘宛榕, 赵林. 颅内生殖细胞肿瘤的药物治疗[J]. 基础医学与临床, 2024, 44(10): 1350-1356.
[14]	刘林弟, 吕庆杰. GPSM2在肿瘤中作用机制的研究进展[J]. 基础医学与临床, 2024, 44(10): 1447-1450.
[15]	李文超, 李祥生, 李富光, 张志永, 惠磊, 周文科. 长链非编码RNA与疾病[J]. 基础医学与临床, 2024, 44(10): 1465-1469.